1. Home
  2. DFNS vs IGC Comparison

DFNS vs IGC Comparison

Compare DFNS & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DFNS

T3 Defense Inc. Common Stock

N/A

Current Price

$0.60

Market Cap

27.2M

ML Signal

N/A

Logo IGC Pharma Inc.

IGC

IGC Pharma Inc.

HOLD

Current Price

$0.26

Market Cap

25.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DFNS
IGC
Founded
2013
2005
Country
United States
United States
Employees
15
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.2M
25.0M
IPO Year
N/A
2005

Fundamental Metrics

Financial Performance
Metric
DFNS
IGC
Price
$0.60
$0.26
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$5.00
AVG Volume (30 Days)
1.2M
260.6K
Earning Date
05-13-2026
03-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
59.09
EPS
N/A
N/A
Revenue
N/A
$1,271,000.00
Revenue This Year
N/A
$3.54
Revenue Next Year
N/A
$15.12
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.62
$0.24
52 Week High
$2.68
$0.50

Technical Indicators

Market Signals
Indicator
DFNS
IGC
Relative Strength Index (RSI) 19.61 46.02
Support Level N/A $0.25
Resistance Level $2.44 $0.31
Average True Range (ATR) 0.12 0.02
MACD -0.02 -0.00
Stochastic Oscillator 17.99 28.80

Price Performance

Historical Comparison
DFNS
IGC

About DFNS T3 Defense Inc. Common Stock

T3 Defense Inc is a holding company that acquires and operates mission-critical defense businesses involved in national security programs. It focuses on manufacturers with tough customer relationships and solid order backlogs, often capacity-and resource-constrained and specialized areas such as drones and autonomous vehicles, counter-drone systems, main manufacturing, tactical robotics, and AI software and system integration. Through disciplined acquisitions, centralized capital and ideas, and decentralized day-to-day operations, it aims to strengthen essential defense capabilities and build long-term value.

About IGC IGC Pharma Inc.

IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.

Share on Social Networks: